OMAKOR (Omacor)

     Synonym : Omega-3 triglycerides (EPC / DKG = 1,2 / 1-90%), Omega-3-triglycerides [EPA / DHA = 1.2 / 1% to 90%]

     The composition and the form of : 1 CBSA gelatine capsule.

- concentrate K85 omega-3- acid ethyl esters (share eykozapentaenovoy acid ethyl ester-46% share dokozageksaenovoy acid ethyl ester-38%) 1000 mg

alpha-tokoferol 4 mg

a soft-shell capsules zhelatinovoy : gelatin; glitserol; Purified water

in polyethylene bottles of 28 and 100 pc.

     Description pharmaceutical form : Transparent zhelatinovaya soft capsule size 20, the contents of the capsules, oily liquid light amber.

     Description : Contains polyunsaturated fatty acid omega-3 class-eykozapentaenovuyu (EPK) and dokozageksaenovuyu (DGK) - an (of essential) fatty acids.

     The drugs act : Gipolipidemicheskoe.

Omakor reduces triglyceride content as a result of LPONP, moreover, it has an impact on hemostasis by reducing synthesis tromboksana A2 and slightly increasing the time blood coagulability.

     Pharmacokinetics : During and after the intake of fatty acids omega-3 are three main ways of their metabolism :

- fatty acids, first delivered to the liver, where they are included in the various categories of density and sent to the periphery of lipids;

- phospholipids of cell membranes replaced phospholipids density, followed by fatty acids act as precursors of eykozanoidov;

most fatty acids oxidized to provide energy needs.

The concentration of fatty acid omega-3 class-EPK and DGK - phospholipids in the plasma concentration with EPK and DGK included in the cellular membranes.

     Farmakodinamika : Delays synthesis of triglycerides in the liver, because EPK and DGK dismal substantial other fatty acids. Reducing the level of triglycerides is also reducing the number of free fatty acids (increasing peroksisomy beta oxidation of fatty acids) involved in the synthesis of triglycerides. Inhibition of synthesis reduces the level LPONP.

Raising LPVP very little and is not permanent. It is significantly less than the admission fibratov.

Results of observations (over 3.5 years) of patients who took the drug for one Omakor grams a day, showed a significant reduction in the combined rate, which includes deaths from all causes and nonfatal myocardial infarction and stroke.

     Indication : Secondary prevention of myocardial infarction (in combination with other standard methods of treatment statins, antitrombotsitarnymi means beta adrenoblokatorami, ACE inhibitors).

Gipertriglitseridemiya : endogenous gipertriglitseridemiya-as a supplement to the diet, with its lack of effectiveness :

type IV (as monotherapies)

type IIb / III (in combination with statins, when the concentration is high triglycerides).

     Contraindications : Increased susceptibility to a drug component, exogenous gipertriglitseridemiya (giperhilomikronemii type 1), pregnancy and breastfeeding.

A caution-age to 18 years (the effectiveness and safety have not been established), advanced age (over 70), expressed as a violation of liver, the simultaneous application of fibratami or oral anticoagulants, heavy trauma surgery (at the risk of increased bleeding time) .

     Application of pregnancy and breastfeeding : Protivopokazano pregnancy. At the time of treatment should stop breastfeeding.

     Side Effects : From the digestive tract : possible emergence physically or Melbourne to smell or taste the fish, nausea, vomiting, abdominal mark, diarrhoea or constipation.

For the skin : rarely eczema, acne.

Laboratory performance : in patients with moderate gipertriglitseridemiey possible increase in "liver" transaminaz.

Possible allergic reactions.

     Networking : With the simultaneous use of oral anti-times the risk of bleeding. Appointment Omakora with racumin not entail any haemorrhagic complications. However, when combined admission Omakora and racumin or termination of treatment Omakorom protrombinovogo time needed to be monitored.

Not recommended simultaneous application of fibratami.

     Overdosing : Symptoms : may cause side effects or worsening of their symptoms.

Treatment : symptomatic therapy.

     Dosing and Administration : inside, along with food. For secondary prevention of myocardial infarction to take on one CBSA. a day. Duration of treatment on the advice of a doctor.

Gipertriglitseridemiya : initial dose-2 CBSA. a day. In the absence of therapeutic effect can increase the doses of 4 CBSA. a day. Duration of treatment on the advice of a doctor.

     Precautions : no effect on the ability to drive a car and maintain the machines.

     Special instructions : In connection with the moderate increase in bleeding time (in the employment of high-dose-4 CBSA). Required monitoring patients antikoagulyantnuyu therapy, as appropriate, correct doses of the anticoagulant. This therapy does not preclude the need for conventional treatment in such patients control. It should take into account the increased number of bleeding in patients with increased risk of haemorrhage (as a result of severe trauma, surgery, etc.). Experience study secondary endogenous gipertriglitseridemii (especially beyond the control of diabetes) is very limited. There is no clinical experience with the treatment gipertriglitseridemii with fibratami. Before Omakora may moderate increase in "liver" transaminaz. In patients with liver function violation (especially in the employment of high-dose-4 CBSA). A regular monitoring of liver function (ST A and ALT). Details on the preparation Omakor of children, elderly patients over 70 years of age or in patients with liver function no violation.

     Shelf life : 3 years

     Storage conditions : The temperature is not above 25 ° C (not freezing)

Materials allowed to copy only with the active hyperlink to the handbook of medicines